These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 28528764)

  • 1. Dengue vaccine safety signal: Immune enhancement, waning immunity, or chance occurrence?
    Gessner BD; Halsey N
    Vaccine; 2017 Jun; 35(27):3452-3456. PubMed ID: 28528764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease.
    Hadinegoro SR; Arredondo-García JL; Capeding MR; Deseda C; Chotpitayasunondh T; Dietze R; Muhammad Ismail HI; Reynales H; Limkittikul K; Rivera-Medina DM; Tran HN; Bouckenooghe A; Chansinghakul D; Cortés M; Fanouillere K; Forrat R; Frago C; Gailhardou S; Jackson N; Noriega F; Plennevaux E; Wartel TA; Zambrano B; Saville M;
    N Engl J Med; 2015 Sep; 373(13):1195-206. PubMed ID: 26214039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America.
    Arredondo-García JL; Hadinegoro SR; Reynales H; Chua MN; Rivera Medina DM; Chotpitayasunondh T; Tran NH; Deseda CC; Wirawan DN; Cortés Supelano M; Frago C; Langevin E; Coronel D; Laot T; Perroud AP; Sanchez L; Bonaparte M; Limkittikul K; Chansinghakul D; Gailhardou S; Noriega F; Wartel TA; Bouckenooghe A; Zambrano B;
    Clin Microbiol Infect; 2018 Jul; 24(7):755-763. PubMed ID: 29408333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy.
    Sridhar S; Luedtke A; Langevin E; Zhu M; Bonaparte M; Machabert T; Savarino S; Zambrano B; Moureau A; Khromava A; Moodie Z; Westling T; Mascareñas C; Frago C; Cortés M; Chansinghakul D; Noriega F; Bouckenooghe A; Chen J; Ng SP; Gilbert PB; Gurunathan S; DiazGranados CA
    N Engl J Med; 2018 Jul; 379(4):327-340. PubMed ID: 29897841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of tetravalent dengue vaccine in 2-11 year-olds previously vaccinated against yellow fever: randomized, controlled, phase II study in Piura, Peru.
    Lanata CF; Andrade T; Gil AI; Terrones C; Valladolid O; Zambrano B; Saville M; Crevat D
    Vaccine; 2012 Sep; 30(41):5935-41. PubMed ID: 22863660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial.
    Capeding MR; Tran NH; Hadinegoro SR; Ismail HI; Chotpitayasunondh T; Chua MN; Luong CQ; Rusmil K; Wirawan DN; Nallusamy R; Pitisuttithum P; Thisyakorn U; Yoon IK; van der Vliet D; Langevin E; Laot T; Hutagalung Y; Frago C; Boaz M; Wartel TA; Tornieporth NG; Saville M; Bouckenooghe A;
    Lancet; 2014 Oct; 384(9951):1358-65. PubMed ID: 25018116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective and immunological behavior of chimeric yellow fever dengue vaccine.
    Halstead SB; Russell PK
    Vaccine; 2016 Mar; 34(14):1643-7. PubMed ID: 26873054
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines.
    Capeding RZ; Luna IA; Bomasang E; Lupisan S; Lang J; Forrat R; Wartel A; Crevat D
    Vaccine; 2011 May; 29(22):3863-72. PubMed ID: 21477675
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine.
    Wilder-Smith A; Massad E
    Expert Rev Vaccines; 2016; 15(4):437-41. PubMed ID: 26775653
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity.
    Poo J; Galan F; Forrat R; Zambrano B; Lang J; Dayan G
    Pediatr Infect Dis J; 2011 Jan; 30(1):e9-17. PubMed ID: 21042231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dengvaxia sensitizes seronegatives to vaccine enhanced disease regardless of age.
    Halstead SB
    Vaccine; 2017 Nov; 35(47):6355-6358. PubMed ID: 29029938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dengue Vaccine: Considerations before Rollout in Colombia.
    Villabona-Arenas CJ; Ocazionez Jimenez RE; Jimenez Silva CL
    PLoS Negl Trop Dis; 2016 Jun; 10(6):e0004653. PubMed ID: 27280803
    [No Abstract]   [Full Text] [Related]  

  • 13. Addendum to report of the Global Advisory Committee on Vaccine Safety (GACVS), 10-11 June 2015¹. Safety of CYD-TDV dengue vaccine.
    Wkly Epidemiol Rec; 2015 Aug; 90(34):421-3. PubMed ID: 26298882
    [No Abstract]   [Full Text] [Related]  

  • 14. Development of the Sanofi Pasteur tetravalent dengue vaccine: One more step forward.
    Guy B; Briand O; Lang J; Saville M; Jackson N
    Vaccine; 2015 Dec; 33(50):7100-11. PubMed ID: 26475445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccines and immunization strategies for dengue prevention.
    Liu Y; Liu J; Cheng G
    Emerg Microbes Infect; 2016 Jul; 5(7):e77. PubMed ID: 27436365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Critique of World Health Organization Recommendation of a Dengue Vaccine.
    Halstead SB
    J Infect Dis; 2016 Dec; 214(12):1793-1795. PubMed ID: 27496975
    [No Abstract]   [Full Text] [Related]  

  • 17. Assessment of bivalent and tetravalent dengue vaccine formulations in flavivirus-naïve adults in Mexico.
    Dayan GH; Galán-Herrera JF; Forrat R; Zambrano B; Bouckenooghe A; Harenberg A; Guy B; Lang J
    Hum Vaccin Immunother; 2014; 10(10):2853-63. PubMed ID: 25483647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Projected Impact of Dengue Vaccination in Yucatán, Mexico.
    Hladish TJ; Pearson CA; Chao DL; Rojas DP; Recchia GL; Gómez-Dantés H; Halloran ME; Pulliam JR; Longini IM
    PLoS Negl Trop Dis; 2016 May; 10(5):e0004661. PubMed ID: 27227883
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study.
    Rupp R; Luckasen GJ; Kirstein JL; Osorio JE; Santangelo JD; Raanan M; Smith MK; Wallace D; Gordon GS; Stinchcomb DT
    Vaccine; 2015 Nov; 33(46):6351-9. PubMed ID: 26384447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.
    Guy B; Barrere B; Malinowski C; Saville M; Teyssou R; Lang J
    Vaccine; 2011 Sep; 29(42):7229-41. PubMed ID: 21745521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.